UK – NICE rejects Sanofi’s Sarclisa in preliminary guidelines

NICE has published initial guidelines rejecting NHS use of a therapy combination containing Sanofi's Sarclisa (isatuximab) to treat multiple myeloma.

The company proposes that Sarclisa plus pomalidomide and dexamethasone (pom-dex) be used to treat multiple myeloma only in people who have had at least three treatments before.

At this stage of disease, treatment is usually pom-dex, or daratumumab alone (via the Cancer Drugs Fund).

According to NICE’s appraisal consultation document, clinical trial evidence in this group suggests that Sarclisa plus pom-dex delays the disease progressing and increases how long people live compared with pom-dex alone…